Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Octreotide for Injectable Suspension (02503751), Octreotide for Injectable Suspension (02503778). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

OCTREOTIDE

17 general benefit · 1 not a benefit

Other products in the same Health Canada class (H01CB) — coverage varies; not interchangeable

  • Lanreotide (Somatuline Autogel): general benefit

Octreotide Depot · DIN 02567776 · 10mg · injection Kit Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Octreotide Depot · DIN 02567776 Manufacturer: Sterimax Inc.; listing date 2026-08-31 Health Canada: Marketed since 2026-05-28 · brand OCTREOTIDE DEPOT · ATC H01CB02 OCTREOTIDE · form Powder for suspension (sustained-release · route Intramuscular · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 10 MG/VIAL · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Depot: Formulary list price $726.5115/unit (unit not stated in source; not the patient's cost)

Ministry pays: $726.5115 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107015 · Verify on the e-Formulary ↗ (DIN 02567776)

Source record
DIN 02567776: Octreotide Depot Raw flags: sec3=Y Item: 920000332; group id 941; item number 2238; lccId None; manufacturer id STE Source form: Inj Kit Pk; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $726.5115; ministry $726.5115 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02567776 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107015
Interchangeable products
Sandostatin LAR · DIN 02239323 · $726.5115
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02567776
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandostatin LAR · DIN 02239323 · 10mg · injection Kit Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandostatin LAR · DIN 02239323 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02 Health Canada: Marketed since 1999-01-27 · brand SANDOSTATIN LAR · ATC H01CB02 OCTREOTIDE · form Powder for suspension (sustained-release · route Intramuscular · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 10 MG/VIAL · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $726.5115 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62792 · Verify on the e-Formulary ↗ (DIN 02239323)

Source record
DIN 02239323: Sandostatin LAR Raw flags: sec3=Y Item: 920000332; group id 941; item number 2238; lccId None; manufacturer id NOV Source form: Inj Kit Pk; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $1320.9300; ministry $726.5115 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239323 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62792
Interchangeable products
Octreotide Depot · DIN 02567776 · $726.5115
Shortage status: resolved shortage (ended 2025-08-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239323
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide Depot · DIN 02567784 · 20mg · injection Kit Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Octreotide Depot · DIN 02567784 Manufacturer: Sterimax Inc.; listing date 2026-08-31 Health Canada: Marketed since 2026-05-28 · brand OCTREOTIDE DEPOT · ATC H01CB02 OCTREOTIDE · form Powder for suspension (sustained-release · route Intramuscular · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 20 MG/VIAL · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Depot: Formulary list price $938.6190/unit (unit not stated in source; not the patient's cost)

Ministry pays: $938.6190 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107016 · Verify on the e-Formulary ↗ (DIN 02567784)

Source record
DIN 02567784: Octreotide Depot Raw flags: sec3=Y Item: 920000333; group id 941; item number 2239; lccId None; manufacturer id STE Source form: Inj Kit Pk; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $938.6190; ministry $938.6190 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02567784 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107016
Interchangeable products
Sandostatin LAR · DIN 02239324 · $938.6190
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02567784
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandostatin LAR · DIN 02239324 · 20mg · injection Kit Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandostatin LAR · DIN 02239324 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02 Health Canada: Marketed since 1999-01-27 · brand SANDOSTATIN LAR · ATC H01CB02 OCTREOTIDE · form Powder for suspension (sustained-release · route Intramuscular · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 20 MG/VIAL · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $938.6190 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62793 · Verify on the e-Formulary ↗ (DIN 02239324)

Source record
DIN 02239324: Sandostatin LAR Raw flags: sec3=Y Item: 920000333; group id 941; item number 2239; lccId None; manufacturer id NOV Source form: Inj Kit Pk; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $1706.5800; ministry $938.6190 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239324 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62793
Interchangeable products
Octreotide Depot · DIN 02567784 · $938.6190
Shortage status: resolved shortage (ended 2025-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239324
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide Depot · DIN 02567792 · 30mg · injection Kit Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Octreotide Depot · DIN 02567792 Manufacturer: Sterimax Inc.; listing date 2026-08-31 Health Canada: Marketed since 2026-05-29 · brand OCTREOTIDE DEPOT · ATC H01CB02 OCTREOTIDE · form Powder for suspension (sustained-release · route Intramuscular · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 30 MG/VIAL · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Depot: Formulary list price $1094.7600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1094.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107017 · Verify on the e-Formulary ↗ (DIN 02567792)

Source record
DIN 02567792: Octreotide Depot Raw flags: sec3=Y Item: 920000334; group id 941; item number 2240; lccId None; manufacturer id STE Source form: Inj Kit Pk; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $1094.7600; ministry $1094.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02567792 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107017
Interchangeable products
Octreotide for Injectable Suspension · DIN 02503786 · $1094.7600 Sandostatin LAR · DIN 02239325 · $1094.7600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02567792
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandostatin LAR · DIN 02239325 · 30mg · injection Kit Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandostatin LAR · DIN 02239325 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02 Health Canada: Marketed since 1999-01-27 · brand SANDOSTATIN LAR · ATC H01CB02 OCTREOTIDE · form Powder for suspension (sustained-release · route Intramuscular · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 30 MG/VIAL · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1094.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62794 · Verify on the e-Formulary ↗ (DIN 02239325)

Source record
DIN 02239325: Sandostatin LAR Raw flags: sec3=Y Item: 920000334; group id 941; item number 2240; lccId None; manufacturer id NOV Source form: Inj Kit Pk; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $2189.5200; ministry $1094.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239325 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62794
Interchangeable products
Octreotide Depot · DIN 02567792 · $1094.7600 Octreotide for Injectable Suspension · DIN 02503786 · $1094.7600
Shortage status: resolved shortage (ended 2026-03-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239325
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide Acetate Omega · DIN 02248639 · 50mcg/mL · injection solution - 1mL Amp Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Octreotide Acetate Omega · DIN 02248639 Manufacturer: Omega Laboratories Ltd.; listing date 2008-03-25 Health Canada: Marketed since 2004-02-26 · brand OCTREOTIDE ACETATE OMEGA · ATC H01CB02 OCTREOTIDE · form Solution · route Subcutaneous, Intravenous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 50 MCG/ML · company Omega laboratories limited · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Acetate Omega: Formulary list price $4.0080/unit (unit not stated in source; not the patient's cost)

Ministry pays: $4.0080 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72996 · Verify on the e-Formulary ↗ (DIN 02248639)

Source record
DIN 02248639: Octreotide Acetate Omega Raw flags: sec3=Y Item: 920000083; group id 941; item number 2243; lccId None; manufacturer id OMG Source form: Inj Sol - 1mL Amp Pk; strength: 50mcg/mL Recorded listing: General benefit Source prices (unrounded): $4.0080; ministry $4.0080 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248639 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72996
Interchangeable products
Sandostatin · DIN 00839191 · $4.0080
Shortage status: resolved shortage (ended 2024-01-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248639
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandostatin · DIN 00839191 · 50mcg/mL · injection solution - 1mL Amp Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandostatin · DIN 00839191 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02 Health Canada: Marketed since 1998-04-15 · brand SANDOSTATIN · ATC H01CB02 OCTREOTIDE · form Solution · route Intravenous, Subcutaneous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 50 MCG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $4.0080 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9915 · Verify on the e-Formulary ↗ (DIN 00839191)

Source record
DIN 00839191: Sandostatin Raw flags: sec3=Y Item: 920000083; group id 941; item number 2243; lccId None; manufacturer id NOV Source form: Inj Sol - 1mL Amp Pk; strength: 50mcg/mL Recorded listing: General benefit Source prices (unrounded): $5.3440; ministry $4.0080 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00839191 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9915
Interchangeable products
Octreotide Acetate Omega · DIN 02248639 · $4.0080
Shortage status: active shortage (reported 2024-06-17, last updated 2024-10-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00839191
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide Acetate Omega · DIN 02248640 · 100mcg/mL · injection solution

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Octreotide Acetate Omega · DIN 02248640 Manufacturer: Omega Laboratories Ltd.; listing date 2008-03-25 Health Canada: Marketed since 2004-02-26 · brand OCTREOTIDE ACETATE OMEGA · ATC H01CB02 OCTREOTIDE · form Solution · route Intravenous, Subcutaneous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 100 MCG/ML · company Omega laboratories limited · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Acetate Omega: Formulary list price $5.0440/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.0440 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72997 · Verify on the e-Formulary ↗ (DIN 02248640)

Source record
DIN 02248640: Octreotide Acetate Omega Raw flags: sec3=Y Item: 920000084; group id 941; item number 2241; lccId None; manufacturer id OMG Source form: Inj Sol; strength: 100mcg/mL Recorded listing: General benefit Source prices (unrounded): $5.0440; ministry $5.0440 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248640 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72997
Interchangeable products
Octreotide Injection · DIN 02560240 · $5.0440 Sandostatin · DIN 00839205 · $5.0440
Shortage status: active shortage (reported 2026-07-20, estimated to end 2026-11-30, last updated 2026-07-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248640
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide Injection · DIN 02560240 · 100mcg/mL · injection solution

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Octreotide Injection · DIN 02560240 Manufacturer: Sterimax Inc.; listing date 2026-02-27 Health Canada: Marketed since 2026-01-05 · brand OCTREOTIDE INJECTION · ATC H01CB02 OCTREOTIDE · form Solution · route Intravenous, Subcutaneous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 100 MCG/ML · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Injection: Formulary list price $5.0440/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.0440 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106332 · Verify on the e-Formulary ↗ (DIN 02560240)

Source record
DIN 02560240: Octreotide Injection Raw flags: sec3=Y Item: 920000084; group id 941; item number 2241; lccId None; manufacturer id STE Source form: Inj Sol; strength: 100mcg/mL Recorded listing: General benefit Source prices (unrounded): $5.0440; ministry $5.0440 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02560240 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106332
Interchangeable products
Octreotide Acetate Omega · DIN 02248640 · $5.0440 Sandostatin · DIN 00839205 · $5.0440
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02560240
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide Acetate Omega · DIN 02248642 · 200mcg/mL · injection solution - 5mL vial

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Octreotide Acetate Omega · DIN 02248642 Manufacturer: Omega Laboratories Ltd.; listing date 2008-03-25 Health Canada: Marketed since 2004-03-11 · brand OCTREOTIDE ACETATE OMEGA · ATC H01CB02 OCTREOTIDE · form Solution · route Intravenous, Subcutaneous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 200 MCG/ML · company Omega laboratories limited · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Acetate Omega: Formulary list price $48.5150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $48.5150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72999 · Verify on the e-Formulary ↗ (DIN 02248642)

Source record
DIN 02248642: Octreotide Acetate Omega Raw flags: sec3=Y Item: 920000225; group id 941; item number 2244; lccId None; manufacturer id OMG Source form: Inj Sol - 5mL Vial Pk; strength: 200mcg/mL Recorded listing: General benefit Source prices (unrounded): $48.5150; ministry $48.5150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248642 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72999
Interchangeable products
Octreotide Injection · DIN 02560283 · $48.5150 Sandostatin · DIN 02049392 · $48.5150
Shortage status: resolved shortage (ended 2024-09-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248642
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide Injection · DIN 02560283 · 200mcg/mL · injection solution - 5mL vial

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Octreotide Injection · DIN 02560283 Manufacturer: Sterimax Inc.; listing date 2026-02-27 Health Canada: Marketed since 2026-01-07 · brand OCTREOTIDE INJECTION · ATC H01CB02 OCTREOTIDE · form Solution · route Subcutaneous, Intravenous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 200 MCG/ML · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Injection: Formulary list price $48.5150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $48.5150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106336 · Verify on the e-Formulary ↗ (DIN 02560283)

Source record
DIN 02560283: Octreotide Injection Raw flags: sec3=Y Item: 920000225; group id 941; item number 2244; lccId None; manufacturer id STE Source form: Inj Sol - 5mL Vial Pk; strength: 200mcg/mL Recorded listing: General benefit Source prices (unrounded): $48.5150; ministry $48.5150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02560283 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106336
Interchangeable products
Octreotide Acetate Omega · DIN 02248642 · $48.5150 Sandostatin · DIN 02049392 · $48.5150
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02560283
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide Acetate Omega · DIN 02248641 · 500mcg/mL · injection solution

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Octreotide Acetate Omega · DIN 02248641 Manufacturer: Omega Laboratories Ltd.; listing date 2008-03-25 Health Canada: Marketed since 2004-02-26 · brand OCTREOTIDE ACETATE OMEGA · ATC H01CB02 OCTREOTIDE · form Solution · route Intravenous, Subcutaneous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 500 MCG/ML · company Omega laboratories limited · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Acetate Omega: Formulary list price $23.7070/unit (unit not stated in source; not the patient's cost)

Ministry pays: $23.7070 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72998 · Verify on the e-Formulary ↗ (DIN 02248641)

Source record
DIN 02248641: Octreotide Acetate Omega Raw flags: sec3=Y Item: 920000085; group id 941; item number 2242; lccId None; manufacturer id OMG Source form: Inj Sol; strength: 500mcg/mL Recorded listing: General benefit Source prices (unrounded): $23.7070; ministry $23.7070 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248641 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72998
Interchangeable products
Octreotide Injection · DIN 02560291 · $23.7070 Sandostatin · DIN 00839213 · not recorded
Shortage status: active shortage (reported 2026-07-20, estimated to end 2026-12-31, last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248641
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide Injection · DIN 02560291 · 500mcg/mL · injection solution

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Octreotide Injection · DIN 02560291 Manufacturer: Sterimax Inc.; listing date 2026-02-27 Health Canada: Marketed since 2026-01-05 · brand OCTREOTIDE INJECTION · ATC H01CB02 OCTREOTIDE · form Solution · route Subcutaneous, Intravenous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 500 MCG/ML · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide Injection: Formulary list price $23.7070/unit (unit not stated in source; not the patient's cost)

Ministry pays: $23.7070 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106337 · Verify on the e-Formulary ↗ (DIN 02560291)

Source record
DIN 02560291: Octreotide Injection Raw flags: sec3=Y Item: 920000085; group id 941; item number 2242; lccId None; manufacturer id STE Source form: Inj Sol; strength: 500mcg/mL Recorded listing: General benefit Source prices (unrounded): $23.7070; ministry $23.7070 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02560291 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106337
Interchangeable products
Octreotide Acetate Omega · DIN 02248641 · $23.7070 Sandostatin · DIN 00839213 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02560291
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Octreotide for Injectable Suspension · DIN 02503786 · 30mg · injection Kit Pk

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-05-04 — choose a marketed DIN from the same-category list.Discontinued 2026-05-04 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-05-04 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-05-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Octreotide for Injectable Suspension · DIN 02503786 Manufacturer: Teva Canada Limited; listing date 2021-11-30 Health Canada: Cancelled post market since 2026-05-04 · brand OCTREOTIDE FOR INJECTABLE SUSPENSION · ATC H01CB02 OCTREOTIDE · form Powder for suspension (sustained-release, Kit · route Intramuscular · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 30 MG/VIAL · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Octreotide for Injectable Suspension: Formulary list price $1094.7600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1094.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99322 · Verify on the e-Formulary ↗ (DIN 02503786)

Source record
DIN 02503786: Octreotide for Injectable Suspension Raw flags: sec3=Y Item: 920000334; group id 941; item number 2240; lccId None; manufacturer id TEV Source form: Inj Kit Pk; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $1094.7600; ministry $1094.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02503786 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99322
Interchangeable products
Octreotide Depot · DIN 02567792 · $1094.7600 Sandostatin LAR · DIN 02239325 · $1094.7600
Shortage status: discontinued (2026-05-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02503786
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-05-04 — choose a marketed DIN from the same-category list.

Sandostatin · DIN 00839205 · 100mcg/mL · injection solution

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-03-25 — choose a marketed DIN from the same-category list.Discontinued 2024-03-25 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-03-25 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-03-25 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandostatin · DIN 00839205 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02 Health Canada: Cancelled post market since 2024-03-25 · brand SANDOSTATIN · ATC H01CB02 OCTREOTIDE · form Solution · route Subcutaneous, Intravenous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 100 MCG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.0440 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9916 · Verify on the e-Formulary ↗ (DIN 00839205)

Source record
DIN 00839205: Sandostatin Raw flags: sec3=Y Item: 920000084; group id 941; item number 2241; lccId None; manufacturer id NOV Source form: Inj Sol; strength: 100mcg/mL Recorded listing: General benefit Source prices (unrounded): $10.0880; ministry $5.0440 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00839205 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9916
Interchangeable products
Octreotide Acetate Omega · DIN 02248640 · $5.0440 Octreotide Injection · DIN 02560240 · $5.0440
Shortage status: resolved shortage (ended 2025-01-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00839205
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-03-25 — choose a marketed DIN from the same-category list.

Sandostatin · DIN 02049392 · 200mcg/mL · injection solution - 5mL vial

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-25 — choose a marketed DIN from the same-category list.Discontinued 2022-05-25 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-25 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-05-25 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandostatin · DIN 02049392 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02 Health Canada: Cancelled post market since 2022-05-25 · brand SANDOSTATIN · ATC H01CB02 OCTREOTIDE · form Solution · route Intravenous, Subcutaneous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 200 MCG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $48.5150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19627 · Verify on the e-Formulary ↗ (DIN 02049392)

Source record
DIN 02049392: Sandostatin Raw flags: sec3=Y Item: 920000225; group id 941; item number 2244; lccId None; manufacturer id NOV Source form: Inj Sol - 5mL Vial Pk; strength: 200mcg/mL Recorded listing: General benefit Source prices (unrounded): $97.0300; ministry $48.5150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02049392 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19627
Interchangeable products
Octreotide Acetate Omega · DIN 02248642 · $48.5150 Octreotide Injection · DIN 02560283 · $48.5150
Shortage status: discontinued (2022-02-14, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02049392
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-05-25 — choose a marketed DIN from the same-category list.

Sandostatin · DIN 00839213 · 500mcg/mL · injection solution

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-30 — choose a marketed DIN from the same-category list.Discontinued 2018-07-30 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-07-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandostatin · DIN 00839213 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02 Health Canada: Cancelled post market since 2018-07-30 · brand SANDOSTATIN · ATC H01CB02 OCTREOTIDE · form Solution · route Subcutaneous, Intravenous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 500 MCG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Sandostatin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9917 · Verify on the e-Formulary ↗ (DIN 00839213)

Source record
DIN 00839213: Sandostatin Raw flags: notABenefit=Y, sec3=Y Item: 920000085; group id 941; item number 2242; lccId None; manufacturer id NOV Source form: Inj Sol; strength: 500mcg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00839213 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9917
Interchangeable products
Octreotide Acetate Omega · DIN 02248641 · $23.7070 Octreotide Injection · DIN 02560291 · $23.7070
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00839213
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-07-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications SANDOSTATIN® (octreotide Injection) is indicated for: • The control of symptoms in patients with metastatic carcinoid and vasoactive intestinal peptide- secreting tumours (VIPomas) as well as in patients with acromegaly. Data are insufficient to determine whether SANDOSTATIN decreases the size, rate of growth, or development of metastases in patients with these tumours. • The prevention of complications following pancreatic surgery in patients undergoing high-risk procedures. • The emergency management of bleeding gastro-oesophageal varices in patients with cirrhosis and as protection from re-bleeding. SANDOSTATIN is used in association with specific intervention such as endoscopic sclerotherapy. Carcinoid Tumours SANDOSTATIN is indicated for the symptomatic treatment of metastatic carcinoid tumours where it suppresses or inhibits the severe diarrhoea and flushing episodes associated with the disease. Vasoactive Intestinal Peptide Tumours (VIPomas) SANDOSTATIN is indicated for the treatment of the profuse watery diarrhoea associated with VIP- secreting tumours. Significant improvement has been noted in the overall condition of these othe… https://pdf.hres.ca/dpd_pm/00083516.PDF PM date: 2026-02-16 Source product: SANDOSTATIN; DIN 00839191; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Sandostatin · DIN 00839191 Shortage status: active shortage (reported 2024-06-17, last updated 2024-10-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00839191

Check this DIN again

Octreotide Acetate Omega · DIN 02248640 Shortage status: active shortage (reported 2026-07-20, estimated to end 2026-11-30, last updated 2026-07-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248640

Check this DIN again

Octreotide Acetate Omega · DIN 02248641 Shortage status: active shortage (reported 2026-07-20, estimated to end 2026-12-31, last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248641

Check this DIN again

Octreotide for Injectable Suspension · DIN 02503786 Shortage status: discontinued (2026-05-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02503786

Check this DIN again

Sandostatin · DIN 02049392 Shortage status: discontinued (2022-02-14, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02049392

Check this DIN again

Other review policies

For Sandostatin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026